Supraglottic airway devices for blind endotracheal intubation: A systematic review Authors: Jorman H. Tejada-Perdomo, Carlos E. Melo-Moreno, Jesús H. Tovar-Cardozo, Jorge A. Ramos-Castaneda, Silvia Fiorelli, Silvia Fiorelli, Silvia Fiorelli Published: 2024 ABSTRACT IntroductionThe effectiveness of supraglottic airway devices (SGDs) as a strategy for blind endotracheal intubation (ETI) was compared in this study.MethodsA systematic review of clinical trials (CTs) involving SGDs for blind ETI in patients under general anesthesia or simulation manikins, was conducted. CTs that used SGDs for fiberoptic-guided ETI and those conducted in children were excluded. Searches were performed in Embase, MEDLINE (PubMed), Scopus, and LILACS. The primary outcomes examined were the success rate of blind ETI and intubation time. Secondary outcomes were first-attempt intubation success rate and perceived ease of use.ResultsA total of 567 records were identified from databases, and 16 were identified through citation searches. Ultimately, 27 CTs met the inclusion criteria. The Fastrach Intubating Laryngeal Mask Airway (LMA Fastrach), i-gel, Air-Q Intubating Laryngeal Airway, and Supraglottic Airway Laryngopharyngeal Tube (S.A.L.T.) were the most used SGDs for blind ETI. LMA Fastrach was the most frequently compared device in these CTs. Among the studies in patients, LMA Fastrach and i-gel were the devices that showed the shortest intubation time, although it may be influenced by the way intubation time is assessed. The SGDs with the highest overall success rate were i-gel, S.A.L.T., LMA Fastrach, and single-use LMA Fastrach, followed by Air-Q, and the Intubating Laryngeal Tube Suction-Disposable (iLTS-D2), all achieving success rates greater than 90%. AuraGain had the lowest first-attempt and overall success rates for blind ETI with SGDs.ConclusionNew SGDs have not surpassed the LMA Fastrach effectiveness for blind ETI. The single-use LMA Fastrach combines the efficacy of the reusable LMA Fastrach with the features of other SGDs and may be a suitable replacement for them. The I-gel is also a viable alternative for blind ETI, while the AuraGain may not be recommended for this purpose. Introduction Orotracheal intubation is a cornerstone in managing critically ill patients who require a secure airway [1]. However, airway management can sometimes be difficult or beyond the operator’s expertise. Due to a high failure rate of approximately 30% with direct laryngoscopy during intubation attempts by paramedics [2], alternative strategies such as supraglottic airway devices (SGDs), videolaryngoscopes, and other blind endotracheal intubation (ETI) devices have been developed to achieve airway isolation. The use of SGDs has been extensively researched and is considered an accepted and recognized technique within the American Society of Anesthesiologists (ASA) difficult airway algorithm [3], particularly when mask ventilation is inadequate after a failed intubation. The incidence of difficult intubation varies from 0.1% to 10.1% depending on the definition used [4, 5]. In the study by Jayaraj et al., which included 42,805 surgical cases requiring orotracheal intubation, difficult intubation occurred in 0.26% of cases, and failed intubation occurred in 0.03% of cases [6]. The incidence of difficult intubation in patients with difficult intubation criteria ranges from 5.8% to 20% [7–10]. When conventional laryngoscopy fails, SGDs are used as rescue devices to maintain oxygenation and ventilation. Blind ETI using SGDs is an accepted alternative, and several devices facilitate tracheal tube passage [11] with a high success rate [12]. The use of videolaryngoscopy optimized the management of some patients. However, in those whose use was unsuccessful and who required surgical airway management due to the inability to ventilate, problems of poor visualization of the glottis and airway bleeding were observed as causes of failed intubation [6]. Lack of skill in performing rescue surgical procedures or absence of surgical equipment to restore alveolar oxygenation in an emergency will cause anesthesiologists to fail in the primary purpose of securing the airway, which can lead to catastrophic outcomes such as hypoxic brain damage and death [11, 13]. The use of rescue equipment for ventilation and the need for intubation has led to the development of blind intubation devices to meet these airway isolation needs. Dr. Archie Brain developed the Fastrach Intubating Laryngeal Mask Airway (LMA Fastrach) in 1997 in response to the difficulties of achieving blind intubation with the classic laryngeal mask [14]; since then, it has been used as a strategy for blind ETI with some drawbacks, including the cost of the silicone tube it uses. Various devices, such as laryngeal masks and other direct vision devices, such as fibrobronchoscopes and videolaryngoscopes, have been tested as intubation options to overcome these disadvantages. Using laryngeal masks is included as an option in difficult airway management. However, there are clinical situations where isolating the airway with orotracheal intubation is important. Studies have reported high success rates for intubation using SGDs [15–19]. In 2018, a meta-analysis reported the success rate of unassisted intubation with SGDs but did not include data on intubation time or studies involving simulation manikins [20]. Therefore, we propose a systematic review to evaluate the intubation time and success rate of different SGDs as strategies for blind ETI. Materials and methods We developed the protocol for this review in June 2024. This systematic review was conducted according to the recommendations of the Cochrane Collaboration and is presented according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [21]. Eligibility criteria Clinical trials (CTs) comparing different SGDs for blind ETI with other intubation devices were included. The studies involved patients under general anesthesia for surgery or simulation manikins. CTs using SGDs for fiberoptic-guided ETI, those conducted in the pediatric population, and those published in languages other than English, Spanish, or Portuguese were excluded. The studies were also excluded if their methods and design were not properly stated or reported or if the data provided was inadequate. Studies were synthesized using a well‑formulated Population, Intervention, Control, Outcome (PICO) study design (Table 1). 10.1371/journal.pone.0315301.t001Table 1PICOS statement.CriteriaDeterminant Population Patients under general anesthesia, simulation manikins. Intervention Blind endotracheal intubation using SGDs Control Placement of endotracheal tube whit devices other than SGDs. Outcome Primary outcomes:Success rate of blind ETIBlind intubation time whit SGDsSecondary outcomes:First-attempt intubation success ratePerceived ease of use Study design Clinical trialsSGDs = supraglottic airway devices.ETI = endotracheal intubation PICOS statement. SGDs = supraglottic airway devices. ETI = endotracheal intubation Information sources and search strategy The search was conducted by researchers who have experience in scientific literature review. The authors (JHT-P and CEM-M) independently searched the Embase (1974-June 2024), MEDLINE (PubMed) (1946-June 2024), Scopus (2004-June 2024), and LILACS (1982-June 2024) databases. The search was limited to articles written in English, Spanish, or Portuguese and included studies conducted on humans or simulation manikins. The search strategy was built with the support of an expert in scientific literature search and combined free text and MeSH terms using the Boolean operators AND and OR, as shown below: (((((((("Emergency Medical Services"[Mesh]) OR ("Cadaver"[Mesh])) OR ("Manikins"[Mesh])) OR ("Models, Anatomic"[Mesh])) OR (corpse)) OR ("emergency medical services"[MeSH Terms] OR prehospital emergency care[Text Word])) AND (((blind intubation) OR (SUPRAGLOTTIC DEVICE)) OR (extraglottic devices) OR "Intubation, Intratracheal"[Mesh])) AND ((((("Laryngoscopy"[Mesh] OR "Laryngoscopes"[Mesh]) OR (VIDEOLARINGOSCOP*)) OR (video laryngoscopy)) OR (extraglottic devices)) OR (SUPRAGLOTTIC DEVICES))) AND (((((((((((effectiveness) OR ("Efficiency"[Mesh])) OR ("FIRST ATTEMPT")) OR ("FIRST INTENT")) OR ("FIRST TRY")) OR (INTUBATION TIME)) OR ("INTUBATION TIME")) OR ("DIFFICULTY PERCEPTION")) OR ("PERCEPTION OF DIFFICULTY ")). Study selection The principal investigator (JHT-P) and author CEM-M independently reviewed the titles and abstracts to determine their eligibility. After reviewing the titles and abstracts, the inter-reviewer agreement was 91.2%. Disagreements were resolved through discussion and consensus. When disagreements persisted, a third reviewer (JAR-C) made the final decision. Following the review of titles and abstracts, full-text articles were assessed for eligibility. JHT-P and CEM-M conducted a full-text review. In addition, a search was conducted for references that included additional studies. Data extraction Information from the articles was extracted by four reviewers (JHT-P, CEM-M, JAR-C, and JHT-C) using an established format with the following variables: lead author, year of publication, geographic location, language, population that was intubated, number of procedures performed during the study, participants who performed intubation, type of device used and number of procedures performed with each device, intubation time, first-attempt success rate, overall success rate, and perceived ease of use of the ETI device. When data were missing or incomplete, attempts were made to contact the study authors to obtain further information, however, we did not receive a response from them. Risk of bias in studies The authors (JHT-P, CEM-M, JAR-C, JHT-C) examined the quality of the CTs. Two reviewers independently assessed each article using the Cochrane risk-of-bias (RoB) tool from the Cochrane Handbook for Systematic Reviews of Interventions. Quality was assessed by evaluating the following potential sources of bias: random sequence generation, allocation sequence concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective outcome reporting. Each of the domains judged was classified as follows: high risk of bias, low risk of bias, and some concerns [22]. Synthesis of information The studies were described according to the language of the publication, the country where they were conducted, and the participants’ educational level. Additionally, the types of devices used and the perceived ease of use were analyzed. Results In June 2024, the database search identified 567 records, with an additional 16 records found through citation searches. After excluding review articles, case reports, editorials, conference abstracts, clinical opinions, and comments, 56 studies were assessed for eligibility, including the 16 from the citation search. Twenty-four reports were excluded because they had different designs, including a single cadaver study, three were excluded because they involved pediatric populations, one was excluded as a duplicate, and one was excluded because it was in Chinese. Therefore, 27 CTs were included in the final analysis as outlined in the PRISMA flowchart (Fig 1). Flow diagram. Characteristics of included studies The baseline characteristics and description of the CTs that met the inclusion criteria are summarized in Tables 2 and 3. The included studies were published between 2007 and 2022, none were performed in the pre-hospital setting and most were published in English (85.2%) [11, 15, 17–19, 23–40], and only four in Spanish [16, 41–43]. Most studies were prospective randomized [11, 15, 17–19, 23–41, 43], only two were non-randomized [16, 42]. 10.1371/journal.pone.0315301.t002Table 2Basic characteristics of the included studies.Author, year (Country)Intubated Population /n =*Participants/n =Procedures Zuercher, 2022, Swiss Elective surgery patients/n = 99Anesthesiologists/n = 3n = 137 De Rosa, 2018, Italy Manikin/NRSpecialist physician /n = 12n = 87Nursing staff/n = 32Non-medical staff/n = 3 López Correa, 2016, Spain Elective surgery patients/n = 80Anesthesiologists/n = 3n = 119 Ott, 2020, Germany Manikin/NRMedical students/n = 126n = 629 Fun, 2007, Singapore Elective surgery patients/n = 60Anesthesiologists/NRn = 180 Gawlowski, 2017, Poland Manikin/NRParamedics/n = 46n = 276 Melissopoulou, 2014, Greece Manikin /NRNurses /n = 45n = 135 Kurowski, 2015, Poland Manikin /NREmergency Medical Technicians /n = 120n = 480 Uribe-Valencia, 2014, Colombia Manikin /NRMedical students, army first aid and pre-hospital care personnel /n = 90n = 102 Shavit, 2015, Israel Manikin /NRMilitary Doctors/n = 29n = 58 Ott, 2015, Germany Manikin /NRMedical students/n = 64n = 512 Komasawa, 2014, Japan Manikin /NRPhysicians/n = 20.NR Michalek, 2010, United Kingdom Manikin /NRPhysicians/n = 25n = 450 Alonso, 2012, Spain Manikin /NRResident doctors /n = 6.n = 300 Bielski, 2018, Poland Manikin /NRPhysicians/n = 134n = 1206 Szarpak, 2015, Poland Manikin /NRParamedics/n = 210n = 1268 Anuradha, 2017, India Elective surgery patients /n = 80Anesthesiologist/n = 1n = 101 Darlong, 2011, India Elective surgery patients /n = 60NRn = 81 Halwagi, 2012, Canada Elective surgery patients /n = 160Anesthesiologist/n = 1NR Kapoor, 2014, India Elective surgery patients /n = 100Anesthesiologist/n = 1n = 130 Karim, 2011, USA Elective surgery patients /n = 154Anesthesiologists/NRn = 182 Liu, 2008, Singapore Elective surgery patients /n = 271Anesthesiologists/n = 4n = 152 Malhotra, 2016, India Elective surgery patients /n = 120Anesthesiologists/n = 3n = 173 Neoh, 2012, Malaysia Elective surgery patients /n = 160Anesthesiologist/n = 1n = 232 Teoh, 2007, Singapore Elective surgery patients /n = 84Anesthesiologists/n = 2n = 124 Sethi, 2017, India Elective surgery patients /n = 90Anesthesiologist/n = 1n = 133 Garzón, 2014, Spain Elective surgery patients /n = 80Anesthesiologists/n = 3n = 92n = Number of procedures.NR = No record.*Participants = People who perform the intubation procedure. Basic characteristics of the included studies. n = Number of procedures. NR = No record. *Participants = People who perform the intubation procedure. 10.1371/journal.pone.0315301.t003Table 3Characteristics of the included clinical trials.Author, year (Country)Airway devices comparisonIntubation time (seconds)First attempt success rateOverall success ratePerception of ease Zuercher, 2022, Switzerland iLTS-D vs LMA FastrachiLTS-D = 43.6 (SD 14)LMA Fastrach = 50.4 (SD 19)iLTS-D = 42.6% (21/50)aLMA Fastrach = 81.6% (40/49)aiLTS-D = 70% (35/50)aLMA Fastrach = 91.8% (45/49)aNR De Rosa, 2018, Italy Spritztube vs LMA FastrachLMA Fastrach = 79 (IQR 60–90)Spritztube = 90 (IQR 70–110)NRLMA Fastrach = 85% (40/47)bSpritztube = 100% (47/47)bEase of insertionLMA FastrachVery easy = 5Easy = 32Moderate = 4Difficult = 5Very difficult = 1SpritztubeVery easy = 27Easy = 18Moderate = 2Difficult = 0Very difficult = 0 López Correa, 2016, Spain AuraGain vs LMA FastrachNRAuraGain = 13.5% (5/37)aLMA Fastrach = 66.6% (24/36)aAuraGain = 18.9% (7/37)aLMA Fastrach = 73.7% (28/38)aNR Ott, 2020, Germany ILTS-D2 vs LMA FastrachFirst attemptILTS-D2 = 23 (IQR 20–26)LMA Fastrach = 19 (IQR 17–22)Second attemptILTS-D2 = 20 (IQR 17–22)LMA Fastrach = 16 (IQR 15–19)Third attemptILTS-D2 = 18 (IQR 16–21)LMA Fastrach = 15 (IQR 14–18)Fourth attemptILTS-D2 = 18 (IQR 15–22)LMA Fastrach = 15 (IQR 13–18)Fifth attemptILTS-D2 = 16 (IQR 15–20)LMA Fastrach = 14 (IQR 13–17)First attemptILTS-D2 = 98% (62/63)bLMA Fastrach = 100% (63/63)bILTS-D2 = 97.8% (308/315)**bLMA Fastrach = 99.4% (312/314)**bNR Fun, 2007, Singapore LMA Fastrach vs GlideScopeLMA Fastrach = 21 (SD 20.9)GlideScope = 14.3 (SD 17.7)LMA Fastrach = 63.3% (19/30)aGlideScope = 96.6% (29/30)aLMA Fastrach = 90% (27/30)aGlideScope = 96.6% (29/30)aNR Gawlowski, 2017, Poland i-gel vs Macintosh LaringoscopeScenario Ai-gel = 12 (IQR 11–13)ML = 19 (IQR 18–21)Scenario Bi-gel = 11.5 (IQR 11–13)ML = 20 (IQR 18–22)Scenario Ci-gel = 13 (IQR 11–14)ML = 24 (IQR 21–27)Scenario Abi-gel = 95.7% (44/46)ML = 100% (46/46)Scenario Bbi-gel = 100% (46/46)ML = 84.8% (39/46)Scenario Cbi-gel = 100% (46/46)ML = 82.6% (38/47)NREase of useVAS scale1 (Extremely easy) a 10 (Extremely difficult)Scenario Ai-gel = 2 (2–4)ML = 2.5 (2–4)Scenario Bi-gel = 2.5 (2–4)ML = 4.5 (3–6)Scenario Ci-gel = 2.5 (2–4.5)ML = 6 (4.5–7) Melissopoulou, 2014, Greece LMA Fastrach vs i-gelLMA Fastrach(cc) = 21.99 (SD 3.62)i-gel(cc) = 20.00 (SD 3.71)LMA Fastrach(No cc) = 20.60 (SD 3.71)i-gel(No cc) = 18.40 (SD 3.26)LMA Fastrach(cc) = 77.8%bi-gel(cc) = 73.3%bLMA Fastrach(No cc) = 86.7%bi-gel(No cc) = 82.2%bLMA Fastrach(cc) = 84.4%bi-gel(cc) = 82.2%bLMA Fastrach(No cc) = 91.9%bi-gel(No cc) = 83.7%bNR Kurowski, 2015, Poland S.A.L.T vs Macintosh LaryngoscopeS.A.L.T(cc) = 20.42 (SD 7.54)ML(cc) = 39.43 (SD 8.23)S.A.L.T(No cc) = 17.97 (SD 5.33)ML(No cc) = 31.52 (SD 7.23)S.A.L.T(cc) = 82%bML(cc) = 65.42%bS.A.L.T(No cc) = 91%bML(No cc) = 76.54%bS.A.L.T(cc) = 84.33%bML(cc) = 71.23%bS.A.L.T(No cc) = 96.23%bML(No cc) = 82.45%)bNR Uribe-Valencia, 2014, Colombia S.A.L.T vs Not reportedS.A.L.T first attempt = 16 (IQR = 13–20)S.A.L.T second attempt = 19 (IQR = 18–25,75)S.A.L.T thirth attempt = 24(IQR = NR)S.A.L.T = 90% (81/90)bS.A.L.T = 98.8% (89/90)bDifficulty of procedureS.A.L.T =Very easy = 48.9% (44/90)Easy = 47.8% (43/90)No easy nor difficult = 2.2% (2/90)Difficult = 0% (0/90)Very difficult = 1.1% (1/90) Shavit, 2015, Israel LMA Fastrach vs Direct laryngoscopeLMA Fastrach = 54.2 (SD 9.8)DL = 42.8 (SD 9.7)LMA Fastrach = 93.1% (27/29)bDL = 62% (18/29)bNREase of useFive-point Likert Scale1 = Strongly disagree2 = Disagree.3 = Neither agree nor disagree4 = Agree5 = Strongly agreeLMA Fastrach = 4 (IQR 4–5)DL = 3 (IQR 2–4) Ott, 2015, Germany iLTS-D vs LMA FastrachTrial 1iLTS-D = 19 (IQR 16.0–22.75)LMA Fastrach = 19 (IQR 16.0–24.75)Trial 2iLTS-D = 16 (IQR 14.0–19.0)LMA Fastrach = 15 (IQR 12.25–17.0)Trial 3iLTS-D = 15 (IQR 13.0–17.75)LMA Fastrach = 14 (IQR 12.0–16.0)Trial 4iLTS-D = 14 (IQR 12.0–17.0)LMA Fastrach = 14 (IQR 12.0–16.5)Trial 1biLTS-D = 98.4% (63/64)LMA Fastrach = 98.4% (63/64)iLTS-D = 98.8% (253/256)**bLMA Fastrach = 99.6% (255/256)**bDevice qualification1 (best) a 6 (worst)iLTS-D = 1.5 (IQR 1–2)LMA Fastrach = 2 (IQR 1–2) Komasawa, 2014, Japan Air-Q vs aura-i vs i-gel vs LMA FastrachNRNRAir-Q = 78.94% (15/19)baura-i = 73.68% (14/19)bi-gel = 75% (12/16)bLMA Fastrach = 55.55% (10/18)bNR Michalek, 2010, United Kingdom LMA Fastrach vs i-gelNRNRLMA Fastrach = 88.4% (199/225)bi-gel = 50.7% (114/225)bNR Alonso, 2012, Spain LMA Fastrach vs NRLMA Fastrach = 25 (SD 11.71)LMA Fastrach = 84% (252/300)bLMA Fastrach = 97.3% (292/300)bNR Bielski, 2018, Poland i-gel vs Air-Q vs Macintosh Laryngoscopei-gel(No cc) = 19 (IQR 16–25)Air-Q(No cc) = 23 (IQR 16.5–31)ML(No cc) = 24.5 (IQR 21–32)i-gel(cc) = 18.5 (IQR 17–27)Air-Q(cc) = 20.5 (IQR 18–32)ML(cc) = 41.5 (IQR 35–49)i-gel(VADcc) = 19.5 (IQR 17.5–27.5)Air-Q(VADcc) = 22 (IQR 19.5–35)ML(VADcc) = 49.5 (IQR 44–67)i-gel(No cc) = 81.3% (109/134)bAir-Q(No cc) = 74.6% (100/134)bML(No cc) = 71.7% (96/134)bi-gel(cc) = 79.9% (107/134)bAir-Q(cc) = 74.6% (100/134)bML(cc) = 41.8% (56/134)bi-gel(VADcc) = 73.9% (99/134)bAir-Q(VADcc) = 64.9% (87/134)bML(VADcc) = 23.1% (31/134)bi-gel(No cc) = 100% (134/134)bAir-Q(No cc) = 98.5% (132/134)bML(No cc) = 94.8% (127/134)bi-gel(cc) = 100% (134/134)bAir-Q(cc) = 74.6% (100/134)bML(cc) = 41.8% (56/134)bi-gel(VADcc) = 94.8% (127/134)bAir-Q(VADcc) = 85.8% (115/134)bML(VADcc) = 31.3% (42/134)bEase of use (1–100 Scale)i-gel(No cc) = 35 (IQR 27–37)Air-Q(No cc) = 36 (IQR 27.5–40)ML(No cc) = 42 (IQR 36–47)i-gel(cc) = 36 (IQR 26–38)Air-Q(cc) = 38 (IQR 27–44)ML(cc) = 69 (IQR 51–77)i-gel(VADcc) = 36 (IQR 27–39)Air-Q(VADcc) = 40 (IQR 29–46)ML(VADcc) = 80 (IQR 63–84) Szarpak, 2015, Poland LMA Fastrach vs CobraPLA vs S.A.L.T vs air-QLMA Fastrach = 39.9CobraPLA = 32.5S.A.L.T = 17.2 (SD 4.6)air-Q = 49.2 (SD 19.6)LMA Fastrach = 76.7%bCobraPLA = 58.1%bS.A.L.T = 90.5%bair-Q = 54.7%bLMA Fastrach = 86.7%bCobraPLA = 85.7%bS.A.L.T = 100%bair-Q = 71.4%bEase of use1 (Very easy) a 5 (Very difficult)Mean =LMA Fastrach = 2.2CobraPLA = 2.4S.A.L.T = 1.6air-Q = 3.3 Anuradha, 2017, India i-gel vs LMA Fastrachi-gel = 15.88 (SD 2.49)LMA Fastrach = 16.31 (SD 3.04)i-gel = 60% (24/40)aLMA Fastrach = 87.5% (35/40)aI-gel = 72.5% (29/40)aLMA Fastrach = 95% (38/40)aNR Darlong, 2011, India CobraPLA vs LMA FastrachCobraPLA = 9 (IQR 3–106)LMA Fastrach = 4 (IQR 3–90)CobraPLA = 63.33% (19/30)aLMA Fastrach = 70% (21/30)aCobraPLA = 86.7% (26/30)aLMA Fastrach = 90% (27/30)aNR Halwagi, 2012, Canada i-gel vs LMA Fastrachi-gel = 22 (SD 13)LMA Fastrach = 30 (SD 31)i-gel = 69% (55/80)aLMA Fastrach = 74% (59/80)aI-gel = 73% (58/80)aLMA Fastrach = 91% (73/80)aNR Kapoor, 2014, India i-gel vs LMA Fastrachi-gel = 24.04 (SD 9.42)LMA Fastrach = 20.96 (SD 8.23)i-gel = 66% (33/50)aLMA Fastrach = 74% (37/50)ai-gel = 82% (41/50)aLMA Fastrach = 96% (48/50)aNR Karim, 2011, USA LMA Fastrach vs Air-QLMA Fastrach = 27 (IQR 23–32)Air-Q = 35 (IQR 25–155)LMA Fastrach = 94% (71/76)a Air-Q = 70% (54/78)aLMA Fastrach = 99% (75/76)aAir-Q = 77% (60/78)aNR Liu, 2008, Singapore LMA Fastrach vs LMA CTrachLMA Fastrach = 100 (IQR 74–121)LMA CTrach = 116 (IQR 82–156)LMA Fastrach = 67.9% (93/137)aLMA CTrach = 93.3% (125/134)aLMA Fastrach = 96.4% (132/137)aLMA CTrach = 100% (134/134)aNR Malhotra, 2016, India LMA Fastrach vs Air- QLMA Fastrach = 20.15 (SD 15)Air-Q = 15 (SD 5)LMA Fastrach = 81.8% (45/60)aAir-Q = 67.2% (39/60)aLMA Fastrach = 91.6% (55/60)aAir-Q = 96.6% (58/60)aEase of Intubation =EasyModerateDifficultLMA FastrachEasy = 85.4% (47/55)Moderate = 7.2% (4/55)Difficult = 7.2% (4/55)Air-QEasy = 87.9% (51/58)Moderate = 12% (7/58)Difficult = 0 Neoh, 2012, Malaysia Air-Q vs LMA FastrachNRAir-Q = 63.75% (51/80)aLMA Fastrach = 82.3% (65/79)aAir-Q = 75% (60/80)aLMA Fastrach = 97.4% (77/79)aEase of Intubación =Easy/Moderate/Difficult.Air-QEasy = 75% (60/80)Moderate = 0Difficult = 25% (20/80)LMA FastrachEasy = 93.67% (74/79)Moderate = 3.79% (3/79)Difficult = 2.53% (2/79) Teoh, 2007, Singapore Single use LMA Fastrach vs Reusable LMA FastrachSingle use LMA Fastrach = 101.4 (SD 63.2)Reusable LMA Fastrach = 90.4 (SD 46.1)Single use LMA Fastrach = 62.5% (25/40)aReusable LMA Fastrach 67.5% (27/40)aSingle use LMA Fastrach = 100% (40/40)aReusable LMA Fastrach = 100% (40/40)aEase of useVAS0 (very easy) a 10 (very difficult)Single use LMA Fastrach = 10 (IQR 0–100)Reusable LMA Fastrach = 10 (IQR 0–100) Sethi, 2017, India AuraGain vs Air-QAuraGain = 26 (IQR 25–27)Air-Q = 22 (IQR 21–24)AuraGain = 35,6% (16/45)aAir-Q = 68.9% (31/45)aAuraGain = 53.3% (24/45)aAir-Q = 80% (36/45)aEase of Intubación =EasyModerateDifficultImposibleAuraGainEasy = 22.2% (10/45)Moderate = 17.7% (8/45)Difficult = 13.3% (6/45)Imposible = 46.6% (21/45)Air-QEasy = 42.2% (19/45)Moderate = 24.4% (11/45)Difficult = 13.3% (6/45)Imposible = 20% (9/45) Garzón, 2014, Spain LMA Fastrach vs Air-QNRLMA Fastrach = 66.67% (24/36)aAir-Q = 58.33% (14/24)aLMA Fastrach = 78.95%(30/38)aAir-Q = 75% (24/32)aNRiLTS-D = intubating laryngeal tube; ILTS-D2 = intubating laryngeal tube 2; LMA Fastrach = Fastrach intubating laryngeal mask; ML = Macintosh LaryngoscopeS.A.L.T = Supraglottic airway laryngopharyngeal tube; LMA Fastrach(cc) = Fastrach intubating laryngeal mask with chest compressions; i-gel(cc) = i-gel with chest compressionsLMA Fastrach(No cc) = LMA Fastrach without chest compressions; i-gel(No cc) = i-gel without chest compressions; S.A.L.T(cc) = S.A.L.T with chest compressionsS.A.L.T(No cc) = S.A.L.T without chest compressions; DL = Direct laringoscope; VADcc = Difficult airway with continuous chest compression; VAS = Visual Analogue ScaleSD = Standard Deviation.IQR: Interquartile range.NR = No record** = Calculated dataa = Humansb = Manikin Characteristics of the included clinical trials. iLTS-D = intubating laryngeal tube; ILTS-D2 = intubating laryngeal tube 2; LMA Fastrach = Fastrach intubating laryngeal mask; ML = Macintosh Laryngoscope S.A.L.T = Supraglottic airway laryngopharyngeal tube; LMA Fastrach(cc) = Fastrach intubating laryngeal mask with chest compressions; i-gel(cc) = i-gel with chest compressions LMA Fastrach(No cc) = LMA Fastrach without chest compressions; i-gel(No cc) = i-gel without chest compressions; S.A.L.T(cc) = S.A.L.T with chest compressions S.A.L.T(No cc) = S.A.L.T without chest compressions; DL = Direct laringoscope; VADcc = Difficult airway with continuous chest compression; VAS = Visual Analogue Scale SD = Standard Deviation. IQR: Interquartile range. NR = No record ** = Calculated data a = Humans b = Manikin India had the highest number of publications on using devices for blind intubation, with five articles (18.5%) [28, 29, 31, 33, 35]. Poland followed with four articles (14.8%) [19, 24, 27, 40]. Spain (11.1%) [16, 41, 43] and Singapore (11.1%) [15, 32, 39] each had three articles. Germany (7.4%) had two articles [18, 38]. Colombia contributed one study (3.7%) [42] as did Canada [30], Greece [23], Israel [25], Italy [37], Japan [17], Malaysia [34], the United Kingdom [26], and Switzerland [36] each contributed one article (3.7%). SGDs were used on patients in 51.9% of the studies [11, 15, 28–36, 39, 41, 43], and on simulation manikins in 48.1% [16–19, 23–27, 37, 38, 40, 42]. The population performing SGD intubation consisted primarily of anesthesiologists in 44.4% of the studies [11, 15, 26, 28, 31–33, 35, 36, 39, 41, 43], paramedics in 22.2% [19, 24, 25, 34, 40, 42], medical students in 11.1% [18, 38, 42], nurses in 3.7% [23], physicians in 11.1% [17, 27, 37], residents in 7.4% [16, 30], and inexperienced individuals in 3.7% [37]. One study (3.3%) did not report the population involved [29]. Regarding the participants, most studies were conducted with professionals and specialists with some knowledge in the use of SGDs [11, 15–17, 25, 26, 28–36, 39, 41, 43], other studies report participants without experience in SGDs but were subjected to training and instruction prior to the start of the study [18, 19, 23, 24, 27, 37, 38, 40, 42]. Synthesis of results A total of 7,339 procedures were performed; two studies did not report the number of procedures [17, 30]. LMA Fastrach was used as the blind intubation device in 81.5% of the studies [11, 15–19, 23, 25, 26, 28–34, 36–39, 41, 43]. The i-gel [17, 23, 26–28, 30, 31, 40] and Air-Q [11, 17, 19, 27, 33–35, 41] were used in 29.6% of the studies. The S.A.L.T. device was used in 11.1% of the studies [19, 24, 42], followed by AuraGain and ILTS used in 11.1% of the studies [17, 18, 35, 36, 38, 43]. The Cobra Perilaryngeal Airway (CobraPLA) was used in 7.4% of the studies [19, 29], while the Spritztube [37], and single-use LMA Fastrach [15] were each used in only one study. Of the included studies, 16 articles did not report the method used to assess the ease of use of the SGDs [11, 16, 17, 23, 24, 26, 28–32, 36, 38, 39, 41, 43]. There was significant heterogeneity in the assessment methods for perceived ease of use of the SGD. Studies that used a 1-to-5 scale for assessing perceived ease of use reported a rating of “very easy” to “easy” for the S.A.L.T. device [19, 42], “easy” to “moderate” for the LMA Fastrach [19, 37] and CobraPLA [19], and “moderate” to “difficult” for the Air-Q [19]. One study used the 0–10 visual analog scale (VAS), i-gel was a device easy to use [40]. Conversely, the classic and single-use versions of LMA Fastrach were found to be very difficult to use [15]. The only study using the Likert scale reported that participants agreed it was easy to intubate with LMA Fastrach [25]. a. Blind intubation time with SGD Blind intubation time was an outcome that was evaluated in different ways in the studies. Of the 27 articles included in the study, five (18.5%) did not report the time required for intubation [17, 26, 34, 41, 43]. In studies conducted on manikins, the S.A.L.T device had the shortest intubation times, ranging from 16 seconds [42] to 20.42 seconds [24]. The i-gel, in a study by Gawlowski et al., had an intubation time of 11.5 seconds [40]. Among the studies involving patients, LMA Fastrach had intubation times that ranged from 4 seconds [29] to 100 seconds [32] showing high variability, this was due to the way intubation times were evaluated and i-gel had intubation times between 15.88 seconds [28] and 24.04 seconds [31]. Both devices demonstrated the shortest intubation times [11, 15, 28–33, 36, 39] (Table 3). b. First-attempt success rate Three articles did not report the first attempt success rate [17, 26, 37]. The device with the lowest success rate on the first attempt was AuraGain (13.5%) [43], followed by CobraPLA, with success rates ranging from 58.1% to 63.3% [29]. Two studies reported a 100% successful rate on the first attempt using LMA Fastrach and i-gel [38, 40]. The most frequently compared device in the CTs was the LMA Fastrach, followed by the i-gel and Air-Q. Regarding LMA Fastrach, three studies reported a success rate greater than 90% [11, 18, 38], while three studies reported a success rate of 66% [15, 41, 43]. S.A.L.T was reported in three studies with success rates ranging from 82% in scenarios with chest compressions [24] to 91% in scenarios without chest compressions [24, 42] (Table 3). c. Overall success rate Two articles did not report the overall success rate [25, 40]. A 100% success rate was achieved with i-gel, S.A.L.T., LMA Fastrach, and single-use LMA Fastrach [15, 19, 27]. However, it should be noted that in other studies, the modified S.A.L.T., Air-Q, ILTS-D, iLTS-D2, and the devices above mentioned achieved intubation success rates greater than 90% [11, 16, 18, 23, 24, 27–34, 36, 38, 39, 42]. The lowest overall success rate for blind ETI was observed with AuraGain (18.9%) [43] (Table 3). Risk of bias in the study Of the 27 studies, 23 clearly reported random sequence generation methods [11, 15, 17–19, 23–36, 38–41], and 15 described allocation sequence concealment methods [11, 15, 23, 28–36, 39, 41, 43]. None of the studies blinded participants or personnel. Only three studies reported methods for outcome assessment blinding [16, 33, 34]. All CTs were classified with a low risk of bias for the domains “incomplete outcome data” and “selective outcome reporting,” except for one CT [28], which was classified as having some concerns and a high risk of bias in these two domains, respectively. Details of the risk of bias assessment are presented in Fig 2. Risk bias of included studies. “some concerns” are due to lack of detailed reports. Discussion According to the results of our study, the LMA Fastrach is the most studied intubation SGD to date. The difficulties encountered during “blind” insertion have led to the recommendation of using the 90° rotational technique, the use of a lightwand or combined videolaryngoscopy-bougie techniques, which may suggest a tendency to discourage interest in intubation with SGDs [44]. However, all recent guidelines for difficult airway management recommend the use of SGDs as a rescue measure for oxygenation when other resources fail, and even suggest that they should be present on portable difficult airway carts, but the recommendation of which SGDs to use remains unclear [45]. This systematic review summarizes the effectiveness of SGDs in blind ETI in different scenarios, encompassing human subjects and simulation manikins. Additionally, it highlights the wide geographical distribution of the studies, which supports universally representative results. Differences in intubation time were observed when comparing different types of devices. These disparities may be due to heterogeneity in the definitions, forms and methods in which intubation time is assessed, variations in intubation scenarios and the participants’ level of training and experience in SGD management. Studies demonstrated S.A.L.T. as the device with the shortest intubation times. However, since these studies used simulation manikins, the actual intubation time in real-world clinical scenarios might differ [24, 42]. Anand et al. suggest that the insertion time of SGDs in humans could be prolonged due to possible anatomical differences between patients and simulation models, varying degrees of muscle relaxation, and the need to overcome a learning curve [46]. Darlong et al. found that the LMA Fastrach facilitated the passage of the orotracheal tube more swiftly than other devices, possibly due to its rigid handle and body, which stabilize the device and ease the passage of the orotracheal tube into the airway without deviation [29]. Conversely, the single-use LMA Fastrach, Aura-Gain, and Air-Q appeared to take longer to achieve blind ETI. Intubation time with these devices may be longer because, while they can ventilate the patient, they can also move and deflect the tube away from the midline, thereby delaying the passage of the tube through the vocal cords and increasing the risk of airway injury [29, 35]. The LMA Fastrach and i-gel exhibited the highest first-attempt success rates, followed by iLTS-D2 and S.A.L.T., all surpassing an 80% success rate. Darlong et al., in their comparison of CobraPLA to LMA Fastrach, observed a higher blind ETI success rate with the latter, although without statistical significance. Through pilot testing, they identified the potential resistance mechanism of the CobraPLA and directed the PVC tube down the midline without advancing into the perilaryngeal space or esophagus or injuring the airway. The CobraPLA has certain advantages, including ease of insertion and good airway sealing, which reduces overall insertion time. In addition, the CobraPLA does not require special tubing and does not need to be removed after intubation, unlike the LMA Fastrach, whose weight can exert pressure on the hypopharynx even when the cuff is deflated [29]. While it is crucial for the healthcare provider to establish a definitive airway rapidly, maintaining adequate patient ventilation is equally important regardless of the attempts made. Consequently, the overall success rates become paramount. This systematic review revealed that, except for the LMA Fastrach, which was the first device designed for blind ETI, most devices exhibited comparable success rates. CobraPLA, iLTS, and i-gel performed similarly, boasting features that facilitate airway management, softer components, and the convenience of not having to remove the device once intubation is achieved. Ahn et al. noted that the devices with the best overall success rates in unassisted airway management included LMA-CTrach, single-use LMA Fastrach, and Air-Q [20]. Teoh and Lim found no differences in overall success rates or ease of insertion between single-use LMA Fastrach and LMA Fastrach; however, the single-use LMA Fastrach offers some additional advantages, such as the option to use PVC tubes and a reduced risk of disease transmission [15]. The systematic review produced some relevant findings, although we acknowledge several limitations. Firstly, the studies analyzed were methodologically and clinically diverse. Participants performing intubations were from different disciplines, and interventions occurred in diverse settings, encompassing procedures on patients, simulation manikins, and cadavers. Secondly, despite a thorough search, the possibility of overlooking relevant studies, particularly within gray literature, remains. Thirdly, the studies were not blinded to the investigators inserting the tracheal tube using the SGD. Due to the methodological heterogeneity across studies, conducting a meta-analysis to determine the device with the best performance proved unfeasible, constituting another limitation. Lastly, the included CTs had a high risk of bias or some concerns in the assessment of allocation sequence concealment and blinding of outcome assessors, as evaluated using the Cochrane risk-of-bias (RoB) tool. Despite the limitations described above, this systematic review represents the first attempt to comprehensively investigate the effectiveness of different SGDs for blind ETI in different populations, including humans and simulation manikins. The study evaluates multiple SGDs for blind intubation, assessing them based on intubation time, first-attempt intubation rate, and overall success rate. Conclusion This review demonstrates that the new SGDs have not surpassed the LMA Fastrach for blind ETI regarding first-attempt and overall success rates. The single-use LMA Fastrach combines the efficacy of the reusable LMA Fastrach with the features of other SGDs, potentially making it a suitable replacement for the LMA Fastrach for blind ETI. I-gel emerges as a good alternative among SGDs for blind ETI, showing good results in terms of first-attempt success and overall success rates. In contrast, the AuraGain showed the poorest performance for ETI. Although it ventilated the patients, its use for blind ETI may not be recommended. Supporting information PRISMA checklist. (DOCX) PRISMA abstracts checklist. (DOCX) Dataset with the data of the included studies. (XLSX) Risk of bias in the included studies. (DOCX) 18 Jul 2024 Submitted filename: Rebuttal letter.docx 27 Sep 2024 PONE-D-24-29958Supraglottic airway devices for blind endotracheal intubation: A systematic review.PLOS ONE Dear Dr. Tejada, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Nov 11 2024 11:59PM.If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Silvia Fiorelli Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please note that funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript. 3. Thank you for stating the following financial disclosure: “Publication was funded by Universidad Surcolombiana.” Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 4. We note that your Data Availability Statement is currently as follows: “All relevant data are within the manuscript and in Supporting Information files.” Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition). For example, authors should submit the following data: - The values behind the means, standard deviations and other measures reported; - The values used to build graphs; - The points extracted from images for analysis. Authors do not need to submit their entire data set if only a portion of the data was used in the reported study. If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access. Additional Editor Comments: please carefully assess all the reviewers comments [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes Reviewer #3: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: N/A Reviewer #2: Yes Reviewer #3: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: I have stated all my comments in the file attached. This text is just to fill the minimum required characters of 200 in this field, which is not helpful and should be changed to avoid extra (unpaid) work for the reviewers. Reviewer #2: I think this is an important topic which will be very relevant for clinical application. I commend the authors for the hard work they have put into this manuscript. I appreciate the time taken to revise this manuscript from the initial submission to this current submission as a systematic review. I think it is well written, addresses the primary and secondary outcomes Reviewer #3: The topic of using supraglottic airway devices remains relevant despite the increasing use of video laryngoscopes, which do not provide an absolute solution for all patients. For safety reasons, skills in emergency intubation with supraglottic devices should be maintained, and it is important to compare the available devices to choose the most suitable one. The presented study is interesting and well-written. However, the data is heterogeneous, including studies on patients, mannequins, and cadavers, which creates some confusion and makes a meta-analysis difficult. The feedback from previous reviewers has been well incorporated into the new text. However, the inclusion of a single study involving cadavers may introduce more bias than benefit to the analysis and could be excluded to limit the focus to studies involving patients and mannequins, which already exhibit some heterogeneity. Regarding the populations performing supraglottic device intubation, it appears they were individuals already trained in using the device rather than participants in a training study. This clarification would be valuable for interpreting the results. The distribution of devices used seems well represented across continents, with no clustering of studies on a single model in any country or continent. This could also be mentioned in the discussion to reinforce the universality of the message. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Stephan Katzenschlager Reviewer #2: No Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. Submitted filename: Review.docx 30 Oct 2024 Neiva October 29, 2024 Dra. Silvia Fiorelli Academic Editor Journal PLOS ONE Dear Dra Silvia, Thank you very much for reviewing our manuscript titled “Supraglottic airway devices for blind endotracheal intubation: A systematic review” in PLOS ONE. We appreciate the comments made by each of the reviewers and we have responded point by point to each of the questions raised by them. In our opinion, the quality of the manuscript has increased. We have attached a tracked version of the manuscript so you can see how and where we have modified the original manuscript. Looking forward to hearing from you, Sincerely, Jorman Harvey Tejada Perdomo Corresponding Author Journal Requirements: - Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdfand https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf Thank you very much for the clarification. We took into account the editorial standards of the journal. - Please note that funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript. Thank you for your valuable comment. We removed funding-related text from the manuscript. - Thank you for stating the following financial disclosure: “Publication was funded by Universidad Surcolombiana.” Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. Following up on your comment about the role of the funder, the funding statement was included in the cover letter that is attached again in this version. Thank you very much. - We note that your Data Availability Statement is currently as follows: “All relevant data are within the manuscript and in Supporting Information files.” Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition). For example, authors should submit the following data: - The values behind the means, standard deviations and other measures reported; - The values used to build graphs; - The points extracted from images for analysis. Authors do not need to submit their entire data set if only a portion of the data was used in the reported study. If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access. Thank you for your comment. Regarding the data availability statement, this point is also added to the document and all available data are attached as supplementary information files. Reviewer #1: Comments Methods - Comment #1: Have you registered this SR at Prospero? Please state the PROSPERO registration ID in the method section. Thanks for your comment. This systematic review was not registered in PROSPERO; however, we will take this comment into account for our future work. - Comment #2: The search terms used are focused on prehospital emergency medicine. However, in the eligibility criteria, it is stated that “The studies involved patients under general anesthesia for surgery, simulation manikins, or cadavers.” Were no studies found in the prehospital setting? This would result from the search and not an inclusion or exclusion criteria. In-/Exclusion criteria should be defined upfront and, in this case include the prehospital setting. Please revise this issue; if no prehospital studies were found, briefly state this in the results. Thanks for your comment. The search was not limited to studies in prehospital emergency medicine. Some studies in the prehospital setting were identified, however, they were not controlled trials and were therefore not included in the systematic review. With this comment in mind, we have added it in the results. - Comment #3: Please indicate if a professional librarian performed the search and defined the search strategy. The search strategy was built with the support of an expert in scientific literature search. And the search was conducted by researchers who have experience in scientific literature review. We added this information in the methodology section. - Comment #4: Exclusion of pediatric studies: What is the reason for excluding these studies? Airway management is even more time-sensitive in children compared to adults. Further, hypoxia is the leading reversible/preventable cause of cardiac arrest. Since you have identified pediatric studies, I recommend including those in your systematic review and reporting them as a subgroup. This would enhance the quality of your work. We appreciate your comment. We understand and share the reviewer's opinion regarding airway management in children. During the literature search we identified a systematic review of exclusively pediatric population (https://doi.org/10.1038/s41598-023-45173-5), so in this systematic review we focused on supraglottic devices for the adult population. - Comment #5: Contact of the study authors: This is valuable information and a great effort from the team to (try to) contact the study team. How many responses did you get? If none, you can also state this. We contacted some authors and did not receive a response from them. Following this comment, we added in methodology that “we did not receive a response from them” Results - Comment #1: Please comment on how many studies were prospective, retrospective, or randomized controlled trials. This information can also be included in Table 2 or 3. Another reviewer previously mentioned this. We appreciate your evaluation. Following your suggestions, we have added information on the methodological design of the included studies to the results. - Comment #2: It is crucial that you stated who performed the SGD intubation. By “anesthesiologists,” do you mean that the studies were conducted in the OR? For example, Anesthesiologists work as prehospital physicians in Germany due to the lack of a dedicated emergency medicine specialty. I recommend reporting the specialty (anesthesiology, internal medicine, emergency medicine…) as stated in the study or the level of training (resident, consultant). Thanks for your comment. In our review, participants refer to the people who performed the intubation procedure. All studies that had anesthesiologists as participants were conducted in elective surgery patients. We have added a comment in Table 2 clarifying the definition of participants. - Comment #3: You have included studies in humans, mannequins, and cadavers. Please report if the success rates were on humans, mannequins or cadavers. Following your comment, in Table 3 we have indicated the type of intubated population. In this same table you can see the results by outcome. Thank you very much. - Comment #4: Among the studies involving patients, LMA Fastrach and i-gel demonstrated the shortest intubation times (11,19,24,25,27,28,36,37,40,41).” Please state the intubation times. Thank you very much for the accuracy. We have added this information to the results. - Comment #5: You have extracted data on comparing SGA vs. direct or video laryngoscopy. Can you please elaborate on this? This is the proper comparator for a failed airway. Thanks for your comments. In our review, we found four studies that compared SGDs with direct laryngoscopy (Kurowski, Shavit, Bielski, Gawlowski) and in two the comparison was made with video laryngoscopy (Liu, Fun); however, the objective of our review was to evaluate the success rate and blind intubation time with SGDs, as reflected in Table 1. Considering the above, from these six studies in question, only the outcome information of the group that used SGDs for blind intubation purposes was extracted. Discussion: - Comment #1: Differences in intubation time: Please note that the differences can be due to the definitions used for “intubation time.” Were you able to extract the definition from the respective studies? There is a big difference when the intubation time is measured from positioning the ET tube through an already placed LMA compared to when the LMA has to be placed and removed afterward. This should be a part of your discussion and can explain fast intubation times (4 seconds!). Reference 40: “Times for tracheal intubation were measured from the beginning of first insertion of the laryngeal mask conduit to completion of tracheal intubation. This timing included the time required for removal of the laryngeal mask conduit, confirmation of ventilation with capnography, and use of the Macintosh laryngoscope where intubation with the LMA Fastrach ™ or LMA CTrach ™ systems had failed.” Reference 28: “Insertion time (s) (defined as the time taken from the moment the ETT was inserted into the SGA device till an adequate EtCO2 trace was obtained).” If this is not accounted for in your discussion, the blind intubation time should be interpreted cautiously. If there is too much heterogeneity in the definitions used, this should be stated as well. We agree with the reviewer. We have clarified the differences in intubation time in the results and in the discussion. Regarding the intubation time, it was heterogeneous between the studies since this outcome can be evaluated in different ways, such as tube passage time or SGD placement time. - Comment #2: “The LMA Fastrach and i-gel exhibited the highest first-attempt success rates, followed by iLTS-D2 and S.A.L.T., all surpassing an 80% success rate. These results are satisfactory and promising from a clinical perspective.” A rate of 80% is not satisfactory. Current resuscitation guidelines state that an expert needs a 95% success rate within two attempts. This should be the standard against which the SGAs are compared. Please revise your discussion accordingly. Thanks for the precision, we agree to eliminate that part of the discussion. - Comment #3: “While it is crucial for an anesthesiologist to establish a definitive airway rapidly, maintaining adequate patient ventilation is equally important regardless of the attempts made.” It is not only crucial for anesthesiologists. During an elective induction, there is always the (theoretical) possibility of reversing the anesthesia. This is not possible in an emergency setting as the indication for airway management is prevention of hypoxia and death. Thank you for your valuable comment, we agree with what you mention, and we have improved the writing of the text. - Comment #4: There is only one newer study (Zuercher, 2022, which included patients from January 2017 to July 2019!). How has the evolution of video laryngoscopy and the use of styles or bougies affected the relevance of an intubation LMA? Is this still used in routine practice? You could look for recommendations for difficult airway carts (e.g. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369510/) Thank you for your valuable comment. We agree with what you mentioned and have improved the wording of the text. Conclusion: - Comment #1: Please shorten your conclusion. The first two sentences can be omitted. Thanks for your comment. We have introduced the suggested changes in the manuscript. Reviewer #2: Comments - Comment #1: I think this is an important topic which will be very relevant for clinical application. I commend the authors for the hard work they have put into this manuscript. I appreciate the time taken to revise this manuscript from the initial submission to this current submission as a systematic review. I think it is well written, addresses the primary and secondary outcomes Thanks for your comment. We have introduced all the suggested changes in the manuscript and in our opinion, the quality of the manuscript has increased. Reviewer #3: Comments - Comment #1: The topic of using supraglottic airway devices remains relevant despite the increasing use of video laryngoscopes, which do not provide an absolute solution for all patients. For safety reasons, skills in emergency intubation with supraglottic devices should be maintained, and it is important to compare the available devices to choose the most suitable one. The presented study is interesting and well-written. However, the data is heterogeneous, including studies on patients, mannequins, and cadavers, which creates some confusion and makes a meta-analysis difficult. We appreciate your evaluation. In this new version, we excluded one study that used cadaver. In this sense, the results were rewrites. Additionally, in the discussion section we have added like limitation the methodological heterogeneity across studies therefore a meta-analysis could not be performed. - Comment #2: The feedback from previous reviewers has been well incorporated into the new text. However, the inclusion of a single study involving cadavers may introduce more bias than benefit to the analysis and could be excluded to limit the focus to studies involving patients and mannequins, which already exhibit some heterogeneity. Thanks for your comment. We followed your recommendation, and we excluded the study with cadavers. In this sense, the results were rewrites. - Comment #3: Regarding the populations performing supraglottic device intubation, it appears they were individuals already trained in using the device rather than participants in a training study. This clarification would be valuable for interpreting the results. Thank you for your precision. We agree with what you mention, and we have clarified it in the manuscript. - Comment #4: The distribution of devices used seems well represented across continents, with no clustering of studies on a single model in any country or continent. This could also be mentioned in the discussion to reinforce the universality of the message. Thank you for your valuable comment. We have added this information to the discussion. Submitted filename: Response to Reviewers.docx 25 Nov 2024 Supraglottic airway devices for blind endotracheal intubation: A systematic review. PONE-D-24-29958R1 Dear Dr. Jorman H. Tejada, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Silvia Fiorelli Academic Editor PLOS ONE Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: (No Response) Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #2: Thank you to the authors for submitting a revised version of their manuscripts and responding to all comments. I think it is an interesting topic and this manuscript adds to this topic. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Stephan Katzenschlager Reviewer #2: No ********** 28 Nov 2024 PONE-D-24-29958R1 PLOS ONE Dear Dr. Tejada-Perdomo, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Silvia Fiorelli Academic Editor PLOS ONE